argenx SE (ARGX)
| Market Cap | 51.75B |
| Revenue (ttm) | 3.68B |
| Net Income (ttm) | 1.53B |
| Shares Out | 61.37M |
| EPS (ttm) | 23.27 |
| PE Ratio | 33.75 |
| Forward PE | 29.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 268,608 |
| Open | 856.48 |
| Previous Close | 851.02 |
| Day's Range | 838.94 - 857.48 |
| 52-Week Range | 510.06 - 857.48 |
| Beta | -0.11 |
| Analysts | Strong Buy |
| Price Target | 872.12 (+2.04%) |
| Earnings Date | Oct 30, 2025 |
About ARGX
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price target is $872.12, which is an increase of 2.04% from the latest price.
News
Baron International Growth Fund Q3 2025 Contributors And Detractors
Baron International Growth Fund gained 6.04% during the quarter, slightly underperforming its benchmark, the MSCI ACWI ex USA Index. Lynas Rare Earths' shares nearly doubled during the quarter as geop...
argenx SE (ARGX) Q3 2025 Earnings Call Transcript
argenx SE ( ARGX) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Tim Van Hauwermeiren - C...
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any b...
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activity Final ADAPT SC+ results sho...
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagno...
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis patients Real-world evidence and long-term data reinforce VYVGART's sustained...
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda...
FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a s...
argenx SE - Special Call
argenx SE - Special Call Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Roeland Vanhauwaert Peter Ulrichts - Chief Scientific Officer Luc Tru...
argenx: Bullish On This R&D Focused Biotech Stock
argenx's blockbuster Vyvgart drives rapid growth, but heavy reliance on one product and US sales creates concentration risk. The company's robust R&D investment and Immunology Innovation Program fuel ...
Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
argenx SE (NASDAQ:ARGX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Karl Gubitz - Chief Financial Officer Conference Call Participants S...
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
argenx to Present at Upcoming Investor Conferences
August 28, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win
Argenx SE ARGX stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab)...
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegati...
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
August 19, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life
Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts
Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
argenx SE (ARGX) Q2 2025 Earnings Call Transcript
argenx SE (NASDAQ:ARGX) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Karen Masse...
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
$949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS foll...
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
July 24, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ann...
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls
Argenx SE ARGX stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo (efgartigimod alf...